Trial Profile

The First-In-Human Trial of the Humanised Monoclonal Antibody NNC 0151-0000-0000 Blocking the C5A Receptor (C5AR)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Sep 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NN 8209 (Primary) ; Anti-C5a monoclonal antibody; Anti-C5a monoclonal antibody
Indications Rheumatoid arthritis
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use

Most Recent Events

09 Jul 2009 New trial record.
13 Jun 2009 Interim results were reported at EULAR 2009.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com